Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Gardasil 9 for Genital Warts
NCT05087849Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Apr 2022
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in condylomata acuminata, sponsored by University of California, San Francisco. Started Apr 2022; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
condylomata acuminata
Beyond the preview
Go deeper on NCT05087849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05087849.